Drug intelligence / Profile preview

PF-04856884

Development stage: Phase 2
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PF-04856884 (also known as CVX-060) is a humanized monoclonal antibody fused to two peptides that specifically bind to angiopoietin 2 (Ang2; ANGPT2). It acts as a selective Angiopoietin-2 inhibitor with potential anti-angiogenic and antineoplastic activities. The drug was developed for the treatment of cancer, particularly metastatic renal cell carcinoma, and was investigated in combination with axitinib. Its mechanism involves blocking Angiopoietin 2, thereby inhibiting tumor blood vessel formation and growth[1][2][5].

Other names: angiopoietin-2-specific fusion protein PF-04856884angiopoietin2-specific fusion protein PF-04856884angiopoietin 2-specific fusion protein PF-04856884

Targets

ANGPT2 (Angiopoietin-2)

Beyond the preview

Go deeper on PF-04856884.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-04856884.

Explore the full profile